216 related articles for article (PubMed ID: 33752918)
1. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Konecny GE; Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; Ray-Coquard I; Aghajanian C; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Castro C; Green M; Simmons AD; Beltman J; Harding T; Lin KK; Goble S; Maloney L; Kristeleit RS; McNeish IA; Swisher EM; Xiao JJ
Gynecol Oncol; 2021 Jun; 161(3):668-675. PubMed ID: 33752918
[TBL] [Abstract][Full Text] [Related]
2. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
[TBL] [Abstract][Full Text] [Related]
4. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
5. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
[TBL] [Abstract][Full Text] [Related]
6. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM
Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Kristeleit RS; Drew Y; Oza AM; Domchek SM; Banerjee S; Glasspool RM; Balmaña J; Chen LM; Patel MR; Burris HA; Safra T; Borrow J; Lin KK; Goble S; Maloney L; Shapira-Frommer R
Br J Cancer; 2023 Jan; 128(2):255-265. PubMed ID: 36482193
[TBL] [Abstract][Full Text] [Related]
9. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Swisher EM; Kwan TT; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Aghajanian C; Konecny GE; O'Malley DM; Leary A; Provencher D; Welch S; Chen LM; Wahner Hendrickson AE; Ma L; Ghatage P; Kristeleit RS; Dorigo O; Musafer A; Kaufmann SH; Elvin JA; Lin DI; Chambers SK; Dominy E; Vo LT; Goble S; Maloney L; Giordano H; Harding T; Dobrovic A; Scott CL; Lin KK; McNeish IA
Nat Commun; 2021 May; 12(1):2487. PubMed ID: 33941784
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley DM; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; Swisher EM; Maloney L; Goble S; Lin KK; Kwan T; Ledermann JA; Coleman RL
Gynecol Oncol; 2022 Dec; 167(3):404-413. PubMed ID: 36273926
[TBL] [Abstract][Full Text] [Related]
12. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
13. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
[TBL] [Abstract][Full Text] [Related]
14. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Colombo N; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Meunier J; Cameron T; Maloney L; Goble S; Bedel J; Ledermann JA; Coleman RL
Gynecol Oncol; 2020 Oct; 159(1):101-111. PubMed ID: 32861537
[TBL] [Abstract][Full Text] [Related]
15. Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Dal Molin GZ; Westin SN; Coleman RL
Future Oncol; 2018 Dec; 14(30):3101-3110. PubMed ID: 30105925
[TBL] [Abstract][Full Text] [Related]
16. Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
Yubero A; Barquín A; Estévez P; Pajares B; Sánchez L; Reche P; Alarcón J; Calzas J; Gaba L; Fuentes J; Santaballa A; Salvador C; Manso L; Herrero A; Taus Á; Márquez R; Madani J; Merino M; Marquina G; Casado V; Constenla M; Gutiérrez M; Dosil A; González-Martín A
BMC Cancer; 2022 Nov; 22(1):1150. PubMed ID: 36348385
[TBL] [Abstract][Full Text] [Related]
17. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Oaknin A; Oza AM; Lorusso D; Aghajanian C; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Amenedo Gancedo M; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Ledermann JA; Coleman RL
Cancer Med; 2021 Oct; 10(20):7162-7173. PubMed ID: 34549539
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
20. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
